TSBX Stock Overview
A clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Turnstone Biologics Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.49 |
| 52 Week High | US$5.75 |
| 52 Week Low | US$0.40 |
| Beta | 0 |
| 1 Month Change | 2.08% |
| 3 Month Change | -20.76% |
| 1 Year Change | -83.58% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -95.54% |
Recent News & Updates
Shareholder Returns
| TSBX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 2.3% | -3.6% | -2.4% |
| 1Y | -83.6% | -2.6% | 23.4% |
Return vs Industry: TSBX underperformed the US Biotechs industry which returned -2.7% over the past year.
Return vs Market: TSBX underperformed the US Market which returned 23.3% over the past year.
Price Volatility
| TSBX volatility | |
|---|---|
| TSBX Average Weekly Movement | 11.7% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: TSBX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: TSBX's weekly volatility has decreased from 18% to 12% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 81 | Sammy Farah | turnstonebio.com |
Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company’s lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors.
Turnstone Biologics Corp. Fundamentals Summary
| TSBX fundamental statistics | |
|---|---|
| Market cap | US$11.36m |
| Earnings (TTM) | -US$74.41m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.2x
P/E RatioIs TSBX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TSBX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$60.38m |
| Gross Profit | -US$60.38m |
| Other Expenses | US$14.03m |
| Earnings | -US$74.41m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.22 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did TSBX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 18:08 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Turnstone Biologics Corp. is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Geoffrey Meacham | BofA Global Research |
| Charlie Yang | BofA Global Research |
| Daina Graybosch | Leerink Partners LLC |